Insmed Incorporated (NASDAQ:INSM) Shares Bought by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. grew its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 217.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 57,500 shares of the biopharmaceutical company's stock after buying an additional 39,400 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Insmed were worth $4,198,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. V Square Quantitative Management LLC purchased a new stake in Insmed in the 3rd quarter worth approximately $30,000. GAMMA Investing LLC boosted its holdings in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 224 shares in the last quarter. First Horizon Advisors Inc. grew its position in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 287 shares during the period. Exchange Traded Concepts LLC increased its holdings in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock valued at $55,000 after buying an additional 627 shares in the last quarter. Finally, CWM LLC raised its position in shares of Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 155 shares during the period.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. This represents a 11.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. This trade represents a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock valued at $5,765,446 over the last ninety days. Company insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. StockNews.com cut Insmed from a "hold" rating to a "sell" rating in a report on Friday, August 9th. JPMorgan Chase & Co. upped their target price on Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research note on Friday, November 22nd. UBS Group lifted their price target on shares of Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a report on Monday, September 9th. Finally, Truist Financial reiterated a "buy" rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $83.67.

Insmed Trading Down 0.0 %

Insmed stock traded down $0.03 during trading on Thursday, reaching $75.33. 2,244,301 shares of the company were exchanged, compared to its average volume of 2,215,028. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock's 50 day simple moving average is $72.31 and its two-hundred day simple moving average is $69.10. The company has a market capitalization of $13.48 billion, a P/E ratio of -13.57 and a beta of 1.10. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same quarter in the previous year, the company posted ($1.10) EPS. The firm's revenue for the quarter was up 18.1% on a year-over-year basis. On average, equities research analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.